Free Trial

Bluejay Diagnostics (BJDX) Competitors

Bluejay Diagnostics logo
$1.56 -0.01 (-0.32%)
As of 02:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BJDX vs. CODX, SSKN, LFWD, TNON, ICU, POAI, SINT, LUCY, STRR, and STSS

Should you be buying Bluejay Diagnostics stock or one of its competitors? The main competitors of Bluejay Diagnostics include Co-Diagnostics (CODX), Strata Skin Sciences (SSKN), Lifeward (LFWD), Tenon Medical (TNON), SeaStar Medical (ICU), Predictive Oncology (POAI), SINTX TECHNOLOGIES (SINT), Innovative Eyewear (LUCY), Star Equity (STRR), and Sharps Technology (STSS). These companies are all part of the "medical equipment" industry.

Bluejay Diagnostics vs. Its Competitors

Co-Diagnostics (NASDAQ:CODX) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Co-Diagnostics currently has a consensus target price of $5.50, suggesting a potential upside of 1,885.56%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, research analysts clearly believe Co-Diagnostics is more favorable than Bluejay Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Co-Diagnostics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
Bluejay Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Bluejay Diagnostics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -1,025.45%. Co-Diagnostics' return on equity of -60.16% beat Bluejay Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Co-Diagnostics-1,025.45% -60.16% -52.69%
Bluejay Diagnostics N/A -322.46%-262.96%

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 8.4% of Co-Diagnostics shares are owned by company insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Co-Diagnostics and Co-Diagnostics both had 1 articles in the media. Bluejay Diagnostics' average media sentiment score of 1.89 beat Co-Diagnostics' score of 1.87 indicating that Bluejay Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Co-Diagnostics Very Positive
Bluejay Diagnostics Very Positive

Co-Diagnostics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Bluejay Diagnostics has lower revenue, but higher earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Co-Diagnostics$3.91M2.38-$37.64M-$1.17-0.24
Bluejay Diagnostics$250K9.33-$7.72M-$379.740.00

Summary

Co-Diagnostics beats Bluejay Diagnostics on 10 of the 16 factors compared between the two stocks.

Get Bluejay Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BJDX vs. The Competition

MetricBluejay DiagnosticsMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$2.33M$6.98B$5.71B$9.51B
Dividend YieldN/A1.28%4.60%3.99%
P/E Ratio0.0025.4128.0720.02
Price / Sales9.3346.77459.47103.02
Price / CashN/A20.6736.5558.97
Price / Book0.154.738.615.88
Net Income-$7.72M$176.14M$3.24B$258.50M
7 Day Performance-0.32%2.59%3.83%2.03%
1 Month Performance-0.95%3.25%10.40%12.52%
1 Year Performance-95.12%7.18%34.13%19.07%

Bluejay Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BJDX
Bluejay Diagnostics
1.2666 of 5 stars
$1.57
-0.3%
N/A-94.4%$2.33M$250K0.009Positive News
CODX
Co-Diagnostics
4.311 of 5 stars
$0.28
+1.4%
$5.50
+1,840.7%
-76.1%$9.38M$3.91M-0.24100High Trading Volume
SSKN
Strata Skin Sciences
3.2093 of 5 stars
$2.21
+0.5%
$6.00
+171.5%
-39.9%$9.18M$33.56M0.00120
LFWD
Lifeward
2.5222 of 5 stars
$0.74
+1.1%
$9.00
+1,119.5%
-78.2%$8.04M$25.41M-0.2460
TNON
Tenon Medical
2.3953 of 5 stars
$1.14
+8.1%
$4.67
+309.4%
+73.0%$8.01M$3.28M-0.048
ICU
SeaStar Medical
0.4347 of 5 stars
$0.68
-4.1%
N/A-88.9%$7.95M$140K-0.202
POAI
Predictive Oncology
2.692 of 5 stars
$0.79
-0.6%
$3.00
+282.1%
-25.2%$7.06M$1.62M-0.2630Positive News
SINT
SINTX TECHNOLOGIES
3.3331 of 5 stars
$2.78
+0.4%
$28.00
+907.2%
-46.5%$6.95M$2.89M-0.0540
LUCY
Innovative Eyewear
0.2795 of 5 stars
$2.18
+3.8%
N/A-60.3%$6.50M$1.64M-0.559Gap Up
STRR
Star Equity
3.6356 of 5 stars
$2.04
+2.9%
$5.00
+144.8%
-55.1%$6.37M$53.36M-0.60460
STSS
Sharps Technology
1.0738 of 5 stars
$6.31
+9.4%
N/AN/A$5.88MN/A0.003Positive News

Related Companies and Tools


This page (NASDAQ:BJDX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners